{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:59:22Z","timestamp":1793120362761,"version":"4.5.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T00:00:00Z","timestamp":1540771200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Hellenic Genito-Urinary Cancer Group"},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s10147-018-1361-9","type":"journal-article","created":{"date-parts":[[2018,10,29]],"date-time":"2018-10-29T01:52:43Z","timestamp":1540777963000},"page":"411-419","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["The combination of bevacizumab\/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study"],"prefix":"10.1007","volume":"24","author":[{"given":"Aristotelis","family":"Bamias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Karavasilis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Gavalas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimon","family":"Tzannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Epaminontas","family":"Samantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Aravantinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Koutras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Gkerzelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Euthymios","family":"Kostouros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Koutsoukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flora","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meletios-Athanasios","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,29]]},"reference":[{"issue":"1","key":"1361_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0165-4608(96)00296-8","volume":"93","author":"HJ Decker","year":"1997","unstructured":"Decker HJ, Weidt EJ, Brieger J (1997) The von Hippel-Lindau tumor suppressor gene. A rare and intriguing disease opening new insight into basic mechanisms of carcinogenesis. Cancer Genet Cytogenet 93(1):74\u201383","journal-title":"Cancer Genet Cytogenet"},{"issue":"5","key":"1361_CR2","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","volume":"23","author":"BI Rini","year":"2005","unstructured":"Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23(5):1028\u20131043. \n                    https:\/\/doi.org\/10.1200\/JCO.2005.01.186","journal-title":"J Clin Oncol"},{"issue":"9605","key":"1361_CR3","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103\u20132111. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(07)61904-7","journal-title":"Lancet"},{"issue":"2","key":"1361_CR4","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356(2):115\u2013124. \n                    https:\/\/doi.org\/10.1056\/NEJMoa065044","journal-title":"N Engl J Med"},{"issue":"6","key":"1361_CR5","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28(6):1061\u20131068. \n                    https:\/\/doi.org\/10.1200\/JCO.2009.23.9764","journal-title":"J Clin Oncol"},{"issue":"6733","key":"1361_CR6","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/20459","volume":"399","author":"PH Maxwell","year":"1999","unstructured":"Maxwell PH, Wiesener MS, Chang GW et al (1999) The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399(6733):271\u2013275. \n                    https:\/\/doi.org\/10.1038\/20459","journal-title":"Nature"},{"issue":"9637","key":"1361_CR7","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","volume":"372","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372(9637):449\u2013456. \n                    https:\/\/doi.org\/10.1016\/S0140-6736(08)61039-9","journal-title":"Lancet"},{"issue":"10","key":"1361_CR8","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1172\/JCI24612","volume":"116","author":"MR Mancuso","year":"2006","unstructured":"Mancuso MR, Davis R, Norberg SM et al (2006) Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest 116(10):2610\u20132621. \n                    https:\/\/doi.org\/10.1172\/JCI24612","journal-title":"J Clin Invest"},{"issue":"6","key":"1361_CR9","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1158\/0008-5472.CAN-06-4102","volume":"67","author":"RK Jain","year":"2007","unstructured":"Jain RK, Tong RT, Munn LL (2007) Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 67(6):2729\u20132735. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-4102","journal-title":"Cancer Res"},{"issue":"10","key":"1361_CR10","doi-asserted-by":"publisher","first-page":"2522","DOI":"10.1158\/1535-7163.MCT-06-0071","volume":"5","author":"T Ikezoe","year":"2006","unstructured":"Ikezoe T, Nishioka C, Tasaka T et al (2006) The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 5(10):2522\u20132530. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-06-0071","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"1361_CR11","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3816\/CGC.2008.n.002","volume":"6","author":"TK Choueiri","year":"2008","unstructured":"Choueiri TK (2008) Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. Clin Genitourin Cancer 6(1):15\u201320. \n                    https:\/\/doi.org\/10.3816\/CGC.2008.n.002","journal-title":"Clin Genitourin Cancer"},{"issue":"7","key":"1361_CR12","first-page":"1992","volume":"7","author":"AL Harris","year":"2001","unstructured":"Harris AL, Reusch P, Barleon B et al (2001) Soluble Tie2 and Flt1 extracellular domains in serum of patients with renal cancer and response to antiangiogenic therapy. Clin Cancer Res 7(7):1992\u20131997","journal-title":"Clin Cancer Res"},{"issue":"5","key":"1361_CR13","first-page":"2291","volume":"36","author":"AA Cumpanas","year":"2016","unstructured":"Cumpanas AA, Cimpean AM, Ferician O et al (2016) The involvement of PDGF-B\/pdgfrbeta axis in the resistance to antiangiogenic and antivascular therapy in renal cancer. Anticancer Res 36(5):2291\u20132295","journal-title":"Anticancer Res"},{"issue":"4","key":"1361_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.ccr.2005.09.005","volume":"8","author":"O Casanovas","year":"2005","unstructured":"Casanovas O, Hicklin DJ, Bergers G et al (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8(4):299\u2013309. \n                    https:\/\/doi.org\/10.1016\/j.ccr.2005.09.005","journal-title":"Cancer Cell"},{"issue":"7","key":"1361_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1470-2045(11)70124-3","volume":"12","author":"S Negrier","year":"2011","unstructured":"Negrier S, Gravis G, Perol D et al (2011) Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial. Lancet Oncol 12(7):673\u2013680. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(11)70124-3","journal-title":"Lancet Oncol"},{"issue":"3","key":"1361_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ejca.2011.11.027","volume":"48","author":"E Calvo","year":"2012","unstructured":"Calvo E, Escudier B, Motzer RJ et al (2012) Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer 48(3):333\u2013339. \n                    https:\/\/doi.org\/10.1016\/j.ejca.2011.11.027","journal-title":"Eur J Cancer"},{"issue":"18","key":"1361_CR17","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1002\/cncr.25219","volume":"116","author":"RJ Motzer","year":"2010","unstructured":"Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116(18):4256\u20134265. \n                    https:\/\/doi.org\/10.1002\/cncr.25219","journal-title":"Cancer"},{"issue":"6","key":"1361_CR18","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","volume":"14","author":"RJ Motzer","year":"2013","unstructured":"Motzer RJ, Escudier B, Tomczak P et al (2013) Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial. Lancet Oncol 14(6):552\u2013562. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(13)70093-7","journal-title":"Lancet Oncol"},{"issue":"19","key":"1361_CR19","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF et al (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med 373(19):1803\u20131813. \n                    https:\/\/doi.org\/10.1056\/NEJMoa1510665","journal-title":"N Engl J Med"},{"issue":"7","key":"1361_CR20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","volume":"17","author":"TK Choueiri","year":"2016","unstructured":"Choueiri TK, Escudier B, Powles T et al (2016) Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncol 17(7):917\u2013927. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(16)30107-3","journal-title":"Lancet Oncol"},{"issue":"8","key":"1361_CR21","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1200\/JCO.2013.50.5305","volume":"32","author":"BI Rini","year":"2014","unstructured":"Rini BI, Bellmunt J, Clancy J et al (2014) Randomized phase III trial of temsirolimus and bevacizumab versus interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32(8):752\u2013759. \n                    https:\/\/doi.org\/10.1200\/JCO.2013.50.5305","journal-title":"J Clin Oncol"},{"issue":"7","key":"1361_CR22","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1093\/annonc\/mdv170","volume":"26","author":"A Ravaud","year":"2015","unstructured":"Ravaud A, Barrios CH, Alekseev B et al (2015) RECORD-2: phase II randomized study of everolimus and bevacizumab versus interferon alpha-2a and bevacizumab as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 26(7):1378\u20131384. \n                    https:\/\/doi.org\/10.1093\/annonc\/mdv170","journal-title":"Ann Oncol"},{"issue":"3","key":"1361_CR23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s00280-014-2668-5","volume":"75","author":"JR Merchan","year":"2015","unstructured":"Merchan JR, Qin R, Pitot H et al (2015) Safety and activity of temsirolimus and bevacizumab in patients with advanced renal cell carcinoma previously treated with tyrosine kinase inhibitors: a phase 2 consortium study. Cancer Chemother Pharmacol 75(3):485\u2013493. \n                    https:\/\/doi.org\/10.1007\/s00280-014-2668-5","journal-title":"Cancer Chemother Pharmacol"},{"issue":"4","key":"1361_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.clgc.2016.02.007","volume":"14","author":"KM Mahoney","year":"2016","unstructured":"Mahoney KM, Jacobus S, Bhatt RS et al (2016) Phase 2 study of bevacizumab and temsirolimus after VEGFR TKI in metastatic renal cell carcinoma. Clin Genitourin Cancer 14(4):304\u2013313 e306. \n                    https:\/\/doi.org\/10.1016\/j.clgc.2016.02.007","journal-title":"Clin Genitourin Cancer"},{"issue":"15","key":"1361_CR25","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","volume":"16","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Hutson TE, Glen H et al (2015) Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol 16(15):1473\u20131482. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(15)00290-9","journal-title":"Lancet Oncol"},{"issue":"6","key":"1361_CR26","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","volume":"35","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Halabi S, Sanford BL et al (2017) Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the alliance A031203 CABOSUN trial. J Clin Oncol 35(6):591\u2013597. \n                    https:\/\/doi.org\/10.1200\/JCO.2016.70.7398","journal-title":"J Clin Oncol"},{"issue":"4","key":"1361_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/1759-7714.12202","volume":"6","author":"MM Hu","year":"2015","unstructured":"Hu MM, Hu Y, Gao GK et al (2015) Basic fibroblast growth factor shows prognostic impact on survival in operable non-small cell lung cancer patients. Thorac Cancer 6(4):450\u2013457. \n                    https:\/\/doi.org\/10.1111\/1759-7714.12202","journal-title":"Thorac Cancer"},{"issue":"5","key":"1361_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1524-475X.2008.00410.x","volume":"16","author":"S Barrientos","year":"2008","unstructured":"Barrientos S, Stojadinovic O, Golinko MS et al (2008) Growth factors and cytokines in wound healing. Wound Repair Regen 16(5):585\u2013601. \n                    https:\/\/doi.org\/10.1111\/j.1524-475X.2008.00410.x","journal-title":"Wound Repair Regen"},{"issue":"3","key":"1361_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/S1470-2045(14)70030-0","volume":"15","author":"RJ Motzer","year":"2014","unstructured":"Motzer RJ, Porta C, Vogelzang NJ et al (2014) Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial. Lancet Oncol 15(3):286\u2013296. \n                    https:\/\/doi.org\/10.1016\/S1470-2045(14)70030-0","journal-title":"Lancet Oncol"},{"issue":"30","key":"1361_CR30","doi-asserted-by":"publisher","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","volume":"33","author":"J Tabernero","year":"2015","unstructured":"Tabernero J, Bahleda R, Dienstmann R et al (2015) Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol 33(30):3401\u20133408. \n                    https:\/\/doi.org\/10.1200\/JCO.2014.60.7341","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-018-1361-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-018-1361-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,28]],"date-time":"2019-10-28T20:31:15Z","timestamp":1572294675000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-018-1361-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,29]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["1361"],"URL":"https:\/\/doi.org\/10.1007\/s10147-018-1361-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,29]]},"assertion":[{"value":"12 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Aristotelis Bamias: Honoraria, Advisory Boards, Research funding: Novartis, Pfizer, Roche, Astra-Zeneca, BMS, Bayer. <i>Vasilios Karavasilis<\/i> Advisory Board: Amgen, Pfizer, Novartis, BI, Lilly, Roche, Astellas, Genesis-Pharma and Janssen. <i>Gerasimos Aravantinos<\/i> Advisory Board: Novartis, BMS, Roche Hellas, Astra Zeneca, Sanofi, Amgen, Genesis Pharma, Merck, Pfizer. Angelos Koutras: Advisory Board: Roche. George Fountzilas. Advisory Board: Pfizer, Sanofi and Roche. Honoraria from Astra-Zeneca. Meletios-Athanassios Dimopoulos: Honoraria, Advisory Board: Janssen, Celgene, Amgen and Takeda.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}